Who Generates Higher Gross Profit? Teva Pharmaceutical Industries Limited or Supernus Pharmaceuticals, Inc.

Teva vs. Supernus: A Decade of Gross Profit Comparison

__timestampSupernus Pharmaceuticals, Inc.Teva Pharmaceutical Industries Limited
Wednesday, January 1, 201411628700011056000000
Thursday, January 1, 201513600400011356000000
Friday, January 1, 201620301700011859000000
Sunday, January 1, 201728702300010825000000
Monday, January 1, 20183935410008296000000
Tuesday, January 1, 20193760950007536000000
Wednesday, January 1, 20204679380007725000000
Friday, January 1, 20215047140007594000000
Saturday, January 1, 20225800170006973000000
Sunday, January 1, 20235237420007646000000
Monday, January 1, 20248064000000
Loading chart...

Unleashing insights

A Tale of Two Pharmaceutical Giants: Teva vs. Supernus

In the competitive world of pharmaceuticals, gross profit is a key indicator of a company's financial health and market position. Over the past decade, Teva Pharmaceutical Industries Limited has consistently outperformed Supernus Pharmaceuticals, Inc. in terms of gross profit. From 2014 to 2023, Teva's gross profit averaged around $9 billion annually, peaking in 2016 with a staggering $11.9 billion. In contrast, Supernus, while showing impressive growth, averaged a gross profit of approximately $360 million, with its highest in 2022 at $580 million.

Despite Teva's dominance, Supernus has shown remarkable growth, increasing its gross profit by nearly 400% from 2014 to 2022. This growth trajectory highlights Supernus's potential in the pharmaceutical sector. As the industry evolves, it will be intriguing to see how these two companies adapt and compete in the coming years.

Published by
U.S. Securities and Exchange Commission

Source link
sec.gov

Date published
17 Jan 2025